The promise and challenges of bioengineered recombinant clotting factors.
about
Engineering next generation proteases.Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.Central venous access devices in patients with hemophilia.Optimal haemophilia care versus the reality.Strategies towards a longer acting factor VIII.Haemophilia therapies.Inhibitor development in haemophilia B: an orphan disease in need of attention.Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.Therapeutic plasma proteins--application of proteomics in process optimization, validation, and analysis of the final product.Pharmacotherapy of haemophilia A.Transgenic mammalian species, generated by somatic cell cloning, in biomedicine, biopharmaceutical industry and human nutrition/dietetics--recent achievements.Clinical advances in hemophilia management.Immune tolerance induction in haemophilia: evidence and the way forward.Historical perspective and future direction of coagulation research.Molecular farming of human cytokines and blood products from plants: challenges in biosynthesis and detection of plant-produced recombinant proteins.Industrial production of clotting factors: Challenges of expression, and choice of host cells.Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.Stable and high-level production of recombinant Factor IX in human hepatic cell line.Structure-function analysis of factor VII activating protease (FSAP): sequence determinants for heparin binding and cellular functions.The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.Physicians' perceptions of adherence to prophylactic clotting factor infusions.European principles of haemophilia care.A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate.Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.
P2860
Q33497078-1BA13139-87E2-4E20-8298-E6BB78A45257Q33533332-F0DC7923-3844-4F80-B844-005B9D82ECACQ36147874-E383FD7F-29B6-47F7-B279-5D32703BA0CFQ36315174-8920F27F-FD16-4BCD-BF4A-61591B235C44Q36399847-3BF8DEFC-214E-4E72-B572-0474C1D92D34Q36473043-F870FA89-069F-45A9-B5E7-56412DE6AD86Q36810282-1648F59F-81D4-4D4F-9C13-97B0CC14D9F8Q36872038-7F479151-F628-40CB-911A-41170D9C8110Q37237490-CDB4F4CE-089D-4287-86C0-464A6630BFA2Q37872258-C776C194-32CA-4349-8D60-56503055F03CQ37891089-56EBEB37-E25E-4DBA-A3AD-8953F1296F57Q37896586-638DA8FC-1C3C-4BC9-BBD4-A9DB86436050Q37900933-E6DC728B-5430-4BFE-9843-1A848E14A428Q37903944-327F3192-3A76-4443-8114-C5F08EEDC2ACQ37903961-C731958F-64A0-475E-8C61-8E1556BDBBCEQ38174581-B6CF72FA-4DC2-4A9A-A0BA-9DDFFD8683E2Q38534584-CAEBC8F6-7837-4AB0-B05F-B5072DF65802Q38731189-4386CFBA-24C5-4ECF-A428-0D23E35CC7BCQ39490991-4A957D1A-88C6-4775-85A1-6CA7E3DBDC3FQ39850743-14D0C57C-114C-4F36-B0A5-5B44AFDF9C46Q40102523-DCA6DC35-9449-496B-A590-C91D64AF81D8Q40216648-9624D5DA-FAE1-459E-8AB2-F0FF5BE8E87FQ45872987-E53D9FE5-1169-48C2-AD23-7BF806352D69Q45874963-5B5A8FAD-382C-427C-90B8-22DFE4D606AAQ45876345-ED56B261-E06B-4141-B84D-B9917A15D4C4Q47324534-F57D3842-A41A-4545-8EB3-AE3C31E2837C
P2860
The promise and challenges of bioengineered recombinant clotting factors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The promise and challenges of bioengineered recombinant clotting factors.
@ast
The promise and challenges of bioengineered recombinant clotting factors.
@en
type
label
The promise and challenges of bioengineered recombinant clotting factors.
@ast
The promise and challenges of bioengineered recombinant clotting factors.
@en
prefLabel
The promise and challenges of bioengineered recombinant clotting factors.
@ast
The promise and challenges of bioengineered recombinant clotting factors.
@en
P2860
P1476
The promise and challenges of bioengineered recombinant clotting factors.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2005.01367.X
P577
2005-08-01T00:00:00Z